(NEXSTAR) – The Food and Drug Administration has issued a recall for a cream produced by a Wisconsin company due to contamination concerns. The cream, intended for treating eczema and similar conditions, was found to contain Staphylococcus aureus.
The product in question, known as Multi-symptom Treatment Cream & Skin Protectant Eczema Cream, is marketed under the MG217 brand by Pharmacal, based in Jackson, Wisconsin. Promoted as a fast-acting, hypoallergenic solution that is “safe for children & babies,” the cream has been distributed both in stores and online across the United States.
Consumers should be aware that the recalled product comes in 6-ounce tubes with the code 5106, a UPC of 012277051067, and carries an expiration date of November 2026.
Staphylococcus aureus, commonly known as staph, is a bacterium that resides in the noses of nearly one-third of people and is typically harmless, according to the Centers for Disease Control and Prevention (CDC).
Despite its usual harmlessness, staph can cause severe and potentially life-threatening infections, especially in medical environments where individuals may be post-surgery or have compromised immune systems. In such cases, it can lead to severe conditions like blood infections, sepsis, pneumonia, heart failure, or stroke, as highlighted by the CDC.
Initial symptoms can show up in the form of skin reactions resembling pimples, boils or other conditions.
Anyone who bought the cream should stop using it and throw it away, according to the FDA.
Anyone with questions about the recall can contact Pharmacal by email (aimho@pharmacalway.com) or phone (800) 558-6614.